Published in:
Open Access
01-12-2013 | Case report
Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib
Authors:
Sabrina Kermiche-Rahali, Aude Di Fiore, Fanny Drieux, Frédéric Di Fiore, Arnaud François, Michel Scotté
Published in:
World Journal of Surgical Oncology
|
Issue 1/2013
Login to get access
Abstract
Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients. We describe the case of a patient who presented with a large HCC in the left liver associated with portal vein thrombosis (PVT). After 9 months of sorafenib treatment, reassessment showed that the tumors had decreased in size with recanalization of the portal vein. A lateral left hepatectomy was performed and pathology showed complete necrosis of the tumor. Sorafenib can downstage HCC in patients with cirrhosis allowing further surgical resection.